

ASX ANNOUNCEMENT

8 November 2021

DurAVR™ selected for PCR London Valves Innovation Session

Brisbane, Australia and Minneapolis, USA. Anteris Technologies Ltd (ASX: AVR) (Anteris or the Company) announces it has been selected to present at this year's PCR London Valves (PCR LV) conference at London, in the innovation session and in the scientific poster abstracts.

PCR LV is the largest international conference that targets the Heart Team (interventional cardiologists, cardiothoracic surgeons, imaging specialists) and focuses solely on heart valves and associated technologies. The conference showcases the latest clinical trial data, novel technologies, and clinical guidelines in heart valvular disease.

The innovation component of PCR LV is reserved for emerging technologies that are original, with clinically relevant/important data that is of interest to the medical community.

DurAVR™ is one of only six presentations selected out of a total of 120 submissions made at this year's meeting.

"We are honoured to have DurAVR™ accepted into the innovation session at this year's PCR London Valves meeting. This rounds out a year of recognition of the DurAVR™ platform and the ADAPT premium anti calcification tissue with its real world evidence at the highest levels of the global clinical and academic community." said Wayne Paterson CEO.

ENDS

About Anteris Technologies Ltd (ASX: AVR)

Anteris Technologies Ltd is a structural heart company delivering clinically superior and durable solutions through better science and better design. Its focus is on developing next generation technologies that help healthcare professionals create life-changing outcomes for patients.

The Anteris DurAVR™ aortic replacement valve addresses the acute need in terms of superior hemodynamic profile as well as chronic needs in its ability to sustain that profile longer over the lifetime of the patient.

The proven benefits of its ADAPT® tissue technology, paired with DurAVR™'s unique 3D single-piece aortic valve design, has the potential to deliver a functional cure to aortic stenosis patients and provide a much-needed solution to the challenges facing heart surgeons today.

Anteris Technologies Ltd Registered Office:

Toowong Tower, Suite 302, Level 3, 9 Sherwood Rd, Toowong, Queensland, 4066

Customer Service

T +61 1300 550 310 | F +61 1300 972 437 | E info@anteristech.com | W anteristech.com

Brisbane • Minneapolis • Geneva • Malaga



Authorisation and Additional information

This announcement was authorised by Mr Wayne Paterson, Chief Executive Officer.

For more information:

Hannah Howlett

WE Communications

E: WE-AUAnterisTech@we-worldwide.com

P: +61 4 5064 8064

www.anteristech.com

Twitter: @AnterisTech

Facebook: www.facebook.com/AnterisTech